辰光医疗(430300) - 2023 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of -10.16 million yuan for 2023, a decrease of 143.27% compared to the previous year's profit of 23.48 million yuan[3]. - The decline in revenue and gross margin is primarily due to Philips' cost control measures, which reduced the proportion of high-margin product sales[5]. - Increased management, sales, and R&D expenses due to strategic adjustments and the introduction of new products, such as the 1.5T MRI system, contributed to the net loss[5]. - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the 2023 annual report[6].